Cytokinetics Heart Drug FDA Approval – Biotech First
- After nearly three decades of research and advancement, Cytokinetics Corporation has received U.S.
- Obstructive Hypertrophic Cardiomyopathy (oHCM) is a genetic heart condition characterized by a thickening of the heart muscle, particularly the left ventricle.
- Myqorzo is a first-in-class cardiac myosin activator.Unlike existing treatments that primarily address symptoms,Myqorzo works by directly enhancing the heart's ability to contract,improving cardiac function without increasing oxygen consumption.
“`html
Myqorzo Approved: FDA Greenlights Cytokinetics’ Heart Failure Drug After 27 Years
Table of Contents
After nearly three decades of research and advancement, Cytokinetics Corporation has received U.S. Food and Drug Administration (FDA) approval for Myqorzo (omecamtiv mecarbil), a novel treatment for obstructive hypertrophic cardiomyopathy (oHCM). The approval marks a pivotal moment for the biotech firm and offers a new therapeutic option for patients with this debilitating heart condition.
Understanding Obstructive Hypertrophic Cardiomyopathy (oHCM)
Obstructive Hypertrophic Cardiomyopathy (oHCM) is a genetic heart condition characterized by a thickening of the heart muscle, particularly the left ventricle. This thickening can obstruct blood flow out of the heart, leading to symptoms like shortness of breath, chest pain, fatigue, and even sudden cardiac death. The American Heart Association estimates that oHCM affects approximately 1 in 200 people.
Myqorzo’s Mechanism of Action and Clinical Trial Data
Myqorzo is a first-in-class cardiac myosin activator.Unlike existing treatments that primarily address symptoms,Myqorzo works by directly enhancing the heart’s ability to contract,improving cardiac function without increasing oxygen consumption. Cytokinetics explains that this unique mechanism helps the heart pump more efficiently.
The FDA approval is based on data from the pivotal METeOR trial, published in the New England Journal of Medicine on December 15, 2023. The trial demonstrated that Myqorzo substantially improved exercise capacity and reduced symptoms in patients with oHCM. Specifically, patients treated with Myqorzo experienced a statistically meaningful betterment in peak oxygen consumption compared to placebo (1.5 mL/kg/min, p=0.0069). The trial involved 288 patients with symptomatic oHCM.
| endpoint | Myqorzo (n=144) | placebo (n=144) | p-value |
|---|---|---|---|
| Change in Peak Oxygen Consumption (mL/kg/min) | 1.5 | -0.2 | 0.0069 |
| NT-proBNP Change from Baseline (%) | -26.1% | -3.1% | 0.0088 |
The trial also showed a statistically significant reduction in NT-proBNP,a biomarker of cardiac stress,in the Myqorzo group.
market Competition and Pricing
Myqorzo will enter a market already occupied by Camzyos (mavacamten) from Bristol Myers Squibb, which received FDA approval in 2022.